<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074711</url>
  </required_header>
  <id_info>
    <org_study_id>R01AR048846</org_study_id>
    <secondary_id>R01AR048846</secondary_id>
    <nct_id>NCT00074711</nct_id>
  </id_info>
  <brief_title>Adding Phosphorus to Osteoporosis Drug Treatment</brief_title>
  <official_title>Bone Sparing by Calcium Salts With and Without Extra Phosphorus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoporosis causes bones to weaken and break more easily. Calcium and phosphorus are two
      minerals that are essential for normal bone formation. Unfortunately, calcium salts commonly
      prescribed in anti-osteoporosis treatment bind phosphorus from food and restrict phosphorus
      available for bone building. Teriparatide is a drug that reduces the risk of fractures by
      increasing bone thickness and strength. Vitamin D is also necessary for strong bones and
      teeth. The purpose of this study is to evaluate the bone-building effectiveness of two
      calcium supplements, one with a source of phosphorus and one without, in combination with
      teriparatide and vitamin D in women with osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis is the most common type of bone disease. Calcium supplements normally used in
      anti-osteoporosis treatment are calcium salts of carbonate or citrate; however, these salts
      bind phosphorus from food in the intestine and restrict phosphorus available for bone
      building. This study will evaluate the efficacy of adding calcium phosphate to a regimen of
      teriparatide and vitamin D in increasing bone mineral density in women with osteoporosis. It
      is hypothesized that the group taking the phosphate-containing calcium supplement will have
      greater gains in bone mineral density (BMD) during the course of the study than the group not
      receiving phosphate.

      All participants will receive teriparatide and vitamin D during the course of the 12-month
      study. Participants will be randomly assigned to one of two groups. One group will receive
      calcium phosphate and the other will receive calcium carbonate. BMD will be measured at spine
      and hip at baseline and at 3, 6, and 12 months of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter.</measure>
    <time_frame>Measured at Baseline</time_frame>
    <description>Bone mineral density (BMD, measured by dual X-ray absorptiometry - DEXA) measured at several intervals during the study. BMD measured as grams per square centimeter (g/cm2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density (BMD) Under Treatment With an Anabolic Agent (Teriparatide).</measure>
    <time_frame>12 months</time_frame>
    <description>The principle outcome measure was change in bone mineral density (BMD) under treatment with an anabolic agent (teriparatide).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Phosphorus, Serum Creatinine, Serum Calcium at 12 Months</measure>
    <time_frame>Measured at baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary Calcium to Creatinine Ratio, Urinary Phosphorus to Creatinine Ratio at 12 Months</measure>
    <time_frame>Measured at baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary N-telopeptide at 12 Months</measure>
    <time_frame>Measured at baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary Hydroxyproline to Creatinine Ratio at 12 Months</measure>
    <time_frame>Measured at baseline and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Calcium Phosphate Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium Carbonate Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium carbonate</intervention_name>
    <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.</description>
    <arm_group_label>Calcium Carbonate Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Phosphate</intervention_name>
    <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.</description>
    <arm_group_label>Calcium Phosphate Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bone mineral density (BMD) T-score less than -1.0

          -  One or more vertebral fractures

          -  Serum creatinine less than 1.3 mg/dL

          -  Serum phosphorus less than 3.6 mg/dL

          -  Daily phosphorus intake below NHANES-III median

          -  Body mass index (BMI) less than 30 kg/m2

        Exclusion Criteria:

          -  Paget's disease or history of osteosarcoma

          -  Systemic corticosteroid therapy

          -  Hyperparathyroidism

          -  Recent history of kidney stone

          -  Anticonvulsant therapy known to alter vitamin D metabolism

          -  Radiation therapy to bone
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P. Heaney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Heaney RP, Recker RR, Watson P, Lappe JM. Phosphate and carbonate salts of calcium support robust bone building in osteoporosis. Am J Clin Nutr. 2010 Jul;92(1):101-5. doi: 10.3945/ajcn.2009.29085. Epub 2010 May 19.</citation>
    <PMID>20484446</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2003</study_first_submitted>
  <study_first_submitted_qc>December 19, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2003</study_first_posted>
  <results_first_submitted>July 3, 2012</results_first_submitted>
  <results_first_submitted_qc>July 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 6, 2016</results_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Calcium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Calcium Phosphate Treatment Group</title>
          <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.</description>
        </group>
        <group group_id="P2">
          <title>Calcium Carbonate Treatment Group</title>
          <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant stopped study drug</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Calcium Phosphate Treatment Group</title>
          <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.</description>
        </group>
        <group group_id="B2">
          <title>Calcium Carbonate Treatment Group</title>
          <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="121"/>
            <count group_id="B3" value="241"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.09" spread="7.02"/>
                    <measurement group_id="B2" value="70.07" spread="6.34"/>
                    <measurement group_id="B3" value="70.07" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter.</title>
        <description>Bone mineral density (BMD, measured by dual X-ray absorptiometry – DEXA) measured at several intervals during the study. BMD measured as grams per square centimeter (g/cm2).</description>
        <time_frame>Measured at Baseline</time_frame>
        <population>Postmenopausal women with spinal osteoporosis.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcium Phosphate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.</description>
          </group>
          <group group_id="O2">
            <title>Calcium Carbonate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter.</title>
          <description>Bone mineral density (BMD, measured by dual X-ray absorptiometry – DEXA) measured at several intervals during the study. BMD measured as grams per square centimeter (g/cm2).</description>
          <population>Postmenopausal women with spinal osteoporosis.</population>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Hip)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.11"/>
                    <measurement group_id="O2" value="0.78" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Spine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.12"/>
                    <measurement group_id="O2" value="0.86" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density (BMD) Under Treatment With an Anabolic Agent (Teriparatide).</title>
        <description>The principle outcome measure was change in bone mineral density (BMD) under treatment with an anabolic agent (teriparatide).</description>
        <time_frame>12 months</time_frame>
        <population>Participants that completed study.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcium Phosphate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.</description>
          </group>
          <group group_id="O2">
            <title>Calcium Carbonate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density (BMD) Under Treatment With an Anabolic Agent (Teriparatide).</title>
          <description>The principle outcome measure was change in bone mineral density (BMD) under treatment with an anabolic agent (teriparatide).</description>
          <population>Participants that completed study.</population>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hip Bone Mineral Density</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01680" spread="0.00227"/>
                    <measurement group_id="O2" value="0.01450" spread="0.00203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spine Bone Mineral Density</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0609" spread="0.00356"/>
                    <measurement group_id="O2" value="0.0607" spread="0.00336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Phosphorus, Serum Creatinine, Serum Calcium at 12 Months</title>
        <time_frame>Measured at baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcium Phosphate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.</description>
          </group>
          <group group_id="O2">
            <title>Calcium Carbonate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Phosphorus, Serum Creatinine, Serum Calcium at 12 Months</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>S Phos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.139" spread="0.045"/>
                    <measurement group_id="O2" value="0.245" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S Crt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="0.012"/>
                    <measurement group_id="O2" value="0.051" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S Ca</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.048" spread="0.041"/>
                    <measurement group_id="O2" value="0.001" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinary Calcium to Creatinine Ratio, Urinary Phosphorus to Creatinine Ratio at 12 Months</title>
        <time_frame>Measured at baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcium Phosphate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.</description>
          </group>
          <group group_id="O2">
            <title>Calcium Carbonate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinary Calcium to Creatinine Ratio, Urinary Phosphorus to Creatinine Ratio at 12 Months</title>
          <units>g/g</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ca to CRT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" spread="0.010"/>
                    <measurement group_id="O2" value="0.011" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ph to CRT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.073" spread="0.025"/>
                    <measurement group_id="O2" value="-0.053" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinary N-telopeptide at 12 Months</title>
        <time_frame>Measured at baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcium Phosphate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.</description>
          </group>
          <group group_id="O2">
            <title>Calcium Carbonate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinary N-telopeptide at 12 Months</title>
          <units>nmol bce/mmol</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="3.42"/>
                    <measurement group_id="O2" value="17.1" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinary Hydroxyproline to Creatinine Ratio at 12 Months</title>
        <time_frame>Measured at baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcium Phosphate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.</description>
          </group>
          <group group_id="O2">
            <title>Calcium Carbonate Treatment Group</title>
            <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinary Hydroxyproline to Creatinine Ratio at 12 Months</title>
          <units>micromol/mmol</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.61" spread="1.25"/>
                    <measurement group_id="O2" value="6.26" spread="0.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Calcium Phosphate Treatment Group</title>
          <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.</description>
        </group>
        <group group_id="E2">
          <title>Calcium Carbonate Treatment Group</title>
          <description>Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Death was judged by the DSMB to be unrelated to the study or its components</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert P Heaney, MD</name_or_title>
      <organization>Creighton University</organization>
      <phone>402 280 4029</phone>
      <email>rpheaney@creighton.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

